Systemic metastasis of hepatocellular carcinoma responsive to multidisciplinary treatment including debulking surgery

Jung, Ho-Youl; Lee, Dong-Shik; Yoon, Sung-Su; Kim, Hong-Jin

doi:10.4174/astr.2014.86.2.100

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCC shows both intrahepatic and extrahepatic metastasis. The most common extrahepatic metastases are the lung, regional lymph nodes, peritoneum, and adrenal glands, but rarely to brain with an approximate rate of 1-6% that is associated with an extremely poor prognosis (13,14). Although the brain is not the most common site for metastatic disease for HCC, some investigators have predicted that the incidence of brain metastases will increase in the future as more patients survive longer (15,16).…”

Section: Discussionmentioning

confidence: 99%

Brain Metastases From Hepatocellular Carcinoma: A Rare Case Report

Dehghan¹,

Kakhki²

2020

ACTA

View full text Add to dashboard Cite

Intrahepatic lesions of hepatocellular carcinoma (HCC) have been controlled by significant advances in treatment, including chemotherapy, surgery, and ablative therapy. Consequently, the number of patients with extrahepatic metastatic lesions has increased, including lung, regional lymph nodes, peritoneum, and adrenal glands, but rarely to the brain. The prognosis of brain metastasis remains poor, with approximately <1 y of survival from the time of diagnosis. Although no guidelines for the brain metastasis of HCC have been developed to date due to the lack of the experiences and pieces of evidence, a molecularly targeted drug, sorafenib, have been used to treat extrahepatic lesions and shown the prolonged survival time. Therefore, the development of standard therapy for brain metastasis following the early diagnosis is essential by accumulating the information of clinical courses and pieces of evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Brain Metastases From Hepatocellular Carcinoma: A Rare Case Report

Dehghan¹,

Kakhki²

2020

ACTA

View full text Add to dashboard Cite

show abstract

“…Systemic metastasis is the important reason for the unsatisfactory prognosis of HCC patients [28] . Increased migratory and invasive ability of cancer cells underlies the systemic metastasis of HCC.…”

Section: Discussionmentioning

confidence: 99%

microRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7

Yang

Huang

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

Dysregulation of microRNAs (miRNAs) is actively involved in the pathogenesis and tumorigenicity of hepatocellular carcinoma (HCC). miR-489 was found to play either oncogenic or tumor suppressive roles in human cancers. Recent study reported that the levels of miR-489 in late recurrent HCC patients were evidently higher than that in early recurrent cases, suggesting that miR-489 may function as a tumor suppressive miRNA in HCC. Yet, the clinical value and biological function of miR-489 remain rarely known in HCC. Here, we presented that miR-489 level in HCC tissues was notably reduced compared to matched non-cancerous specimens. Its decreased level was evidently correlated with adverse clinical parameters and poor prognosis of HCC patients. Accordingly, the levels of miR-489 were obviously down-regulated in HCC cells. Ectopic expression of miR-489 in HCCLM3 and MHCC97H cells prominently inhibits the migration and invasion of tumor cells and reduced lung metastases in vivo, while miR-489 knockdown increased these behaviors of HepG2 and MHCC97L cells. Mechanically, miR-489 negatively regulated matrix metalloproteinase-7 (MMP7) abundance in HCC cells. Herein, MMP7 was found to be a downstream molecule of miR-489 in HCC. An inversely correlation between miR-489 and MMP7 was confirmed in HCC specimens. MMP7 knockdown prohibited cell migration and invasion while MMP7 overexpression showed opposite effects on HCC cells. Furthermore, restoration of MMP7 expression could abrogate the anti-metastatic effects of miR-489 on HCCLM3 cells with enhanced cell migration and invasion. Altogether, miR-489 potentially acts as a prognostic predictor and a drug-target for HCC patients.

show abstract

Long-term outcome of crossover femoro-femoro-popliteal bypass using side-to-side anastomosis in ilio-femoral occlusive disease

2014

View full text Add to dashboard Cite

PurposeDuring crossover femoro-femoro-popliteal sequential bypass (CFFPB) surgery in ilio-femoral occlusive disease, proximal anastomosis of the femoro-popliteal bypass is usually performed distal to the distal anastomosis of the crossover femoro-femoral bypass. If not, it is done with a piggyback configuration. Another method is a side-to-side anastomosis. Its benefit is that this is the only anastomosis made. And it is less bulky compared with the piggyback configuration. This study was aimed to investigate the long-term outcome of CFFPB using side-to-side anastomosis.MethodsFrom Sep 2006 to Aug 2012, 21 patients who underwent CFFPB using side-to-side anastomosis were enrolled. Externally supported polytetrafluoroethylene graft was used as a conduit in all patients. Patient demographic data and procedure details were investigated. Primary graft patency was calculated using the Kaplan-Meier method.ResultsThe mean age of patients was 79 years (range, 62-81 years) and males were 17 (81%). Fifteen patients (71%) had critical limb ischemia. Inflow arteries comprised of 16 common femoral artery (CFA), 4 superficial femoral artery (SFA), and 1 deep femoral artery (DFA). Side-to-side anastomosis was performed on the CFA in 11, SFA in 2, and DFA in 8 patients. During the mean follow-up period of 21 months (1-60 months), 8 patients died. The 1-, 3-, and 5-year primary patency rates were 76%, 63%, and 63%.ConclusionLong-term patency of CFFPB using side-to-side anastomosis was acceptable. It can be one of the treatment options for patients with ilio-femoral occlusive disease.

show abstract

Systemic metastasis of hepatocellular carcinoma responsive to multidisciplinary treatment including debulking surgery

Cited by 3 publications

References 9 publications

Brain Metastases From Hepatocellular Carcinoma: A Rare Case Report

Brain Metastases From Hepatocellular Carcinoma: A Rare Case Report

microRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7

Long-term outcome of crossover femoro-femoro-popliteal bypass using side-to-side anastomosis in ilio-femoral occlusive disease

Contact Info

Product

Resources

About